Drug development in prostate cancer: time to embrace RECIST?
Publication
, Journal Article
Sonpavde, G; Armstrong, AJ
Published in: Lancet Oncol
April 2017
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Lancet Oncol
DOI
EISSN
1474-5488
Publication Date
April 2017
Volume
18
Issue
4
Start / End Page
419 / 421
Location
England
Related Subject Headings
- Treatment Outcome
- Response Evaluation Criteria in Solid Tumors
- Prostatic Neoplasms
- Prostate-Specific Antigen
- Oncology & Carcinogenesis
- Male
- Humans
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Sonpavde, G., & Armstrong, A. J. (2017). Drug development in prostate cancer: time to embrace RECIST? Lancet Oncol, 18(4), 419–421. https://doi.org/10.1016/S1470-2045(17)30149-3
Sonpavde, Guru, and Andrew J. Armstrong. “Drug development in prostate cancer: time to embrace RECIST?” Lancet Oncol 18, no. 4 (April 2017): 419–21. https://doi.org/10.1016/S1470-2045(17)30149-3.
Sonpavde G, Armstrong AJ. Drug development in prostate cancer: time to embrace RECIST? Lancet Oncol. 2017 Apr;18(4):419–21.
Sonpavde, Guru, and Andrew J. Armstrong. “Drug development in prostate cancer: time to embrace RECIST?” Lancet Oncol, vol. 18, no. 4, Apr. 2017, pp. 419–21. Pubmed, doi:10.1016/S1470-2045(17)30149-3.
Sonpavde G, Armstrong AJ. Drug development in prostate cancer: time to embrace RECIST? Lancet Oncol. 2017 Apr;18(4):419–421.
Published In
Lancet Oncol
DOI
EISSN
1474-5488
Publication Date
April 2017
Volume
18
Issue
4
Start / End Page
419 / 421
Location
England
Related Subject Headings
- Treatment Outcome
- Response Evaluation Criteria in Solid Tumors
- Prostatic Neoplasms
- Prostate-Specific Antigen
- Oncology & Carcinogenesis
- Male
- Humans
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis